<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137940">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02001181</url>
  </required_header>
  <id_info>
    <org_study_id>A3921214</org_study_id>
    <nct_id>NCT02001181</nct_id>
  </id_info>
  <brief_title>Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)</brief_title>
  <official_title>A Phase 2a, Multi-Site, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, safety and tolerability of 2%
      tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic
      dermatitis compared to placebo (vehicle) BID for 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>baseline, Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>percent change from baseline at week 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PGA) of Disease Activity</measure>
    <time_frame>week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of subjects with PGA response of &quot;clear&quot; or &quot;almost clear&quot; at week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PGA) of Disease Activity</measure>
    <time_frame>week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of subjects with PGA response of &quot;clear&quot; or &quot;almost clear&quot; and &gt;= 2 grade/point improvement from baseline at week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body surface ares (BSA)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>percent change from baseline in BSA at week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema area and severity index (EASI)  clinical sign severity sum score</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in the EASI clinical sign severity sum score at week 4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <condition>Eczema, Atopic</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib ointment 20mg/g</intervention_name>
    <description>Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ointment (Vehicle)</intervention_name>
    <description>Placebo ointment (vehicle) twice daily (BID) for 4 weeks</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at
             least 6 months prior to Day 1 that has been clinically stable for at least 1 month
             prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of
             Hanifin and Rajka.

          -  Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.

          -  Have atopic dermatitis on the head (including face, but excluding hair bearing
             scalp), neck, trunk (excluding groin and genitals), or limbs (excluding palms and
             soles) covering at least 2% of total body surface area (BSA) and up to and including
             10% of total BSA at Day 1

        Exclusion Criteria:

          -  Evidence of certain skin conditions/infections at baseline

          -  Currently have atopic dermatitis on groin, genitals, palm or soles

          -  Have certain laboratory abnormalities at baseline

          -  Females who are pregnant, breastfeeding, or are of childbearing potential not using
             highly effective contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>SKiN Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology &amp; Cosmetic</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche de Dermatologique du Quebec metropolitain</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921214&amp;StudyName=Tofacitinib%20Ointment%20For%20Atopic%20Dermatitis%20%28Atopic%20Eczema%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Atopic Eczema</keyword>
  <keyword>Eczema</keyword>
  <keyword>topical treatment</keyword>
  <keyword>skin diseases</keyword>
  <keyword>tofacitinib</keyword>
  <keyword>CP-690</keyword>
  <keyword>550</keyword>
  <keyword>Janus Kinase inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
